We are experiencing 4 week turn-around time in review of submissions and resubmissions. We recommend commencing this process concurrently with your ethics submission and allowing at least 8 weeks for registration to be completed from date of first submission. We currently do not have the capacity to expedite reviews.

Note also there are delays to review of updates. We appreciate your patience.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT02996266




Registration number
NCT02996266
Ethics application status
Date submitted
5/12/2016
Date registered
19/12/2016
Date last updated
12/04/2021

Titles & IDs
Public title
Impact of Fever Prevention in Brain Injured Patients
Scientific title
Impact of Fever Prevention in Brain Injured Patients
Secondary ID [1] 0 0
BMD-1111
Universal Trial Number (UTN)
Trial acronym
INTREPID
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Fever 0 0
Ischemic Stroke 0 0
Intracerebral Hemorrhage 0 0
Subarachnoid Hemorrhage 0 0
Condition category
Condition code
Neurological 0 0 0 0
Other neurological disorders
Cardiovascular 0 0 0 0
Diseases of the vasculature and circulation including the lymphatic system
Stroke 0 0 0 0
Haemorrhagic

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Devices - Targeted Temperature Management
Other interventions - Standard Care

Experimental: Fever Prevention - Fever will be prevented using a surface targeted temperature management system

Active Comparator: Standard Care - Standard care in which fever may spontaneously develop


Treatment: Devices: Targeted Temperature Management
Prophylactic normothermia

Other interventions: Standard Care
No intervention to control temperature unless fever occurs

Intervention code [1] 0 0
Treatment: Devices
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Fever Burden - Daily average fever burden (°C-hour)
Timepoint [1] 0 0
Up to 14 days
Secondary outcome [1] 0 0
Primary Neurologic Outcome: Short-Term - Modified Rankin Scale
Timepoint [1] 0 0
3-months post injury
Secondary outcome [2] 0 0
Other Neurologic Outcomes: NIH Stroke Scale Short-Term - NIH Stroke Scale
Timepoint [2] 0 0
3-months post injury
Secondary outcome [3] 0 0
Other Neurologic Outcomes: Barthel Index Short-Term - Barthel Index
Timepoint [3] 0 0
3-months post injury
Secondary outcome [4] 0 0
Other Neurologic Outcomes: Glasgow Outcome Scale Short-Term - Glasgow Outcome Scale
Timepoint [4] 0 0
3-months post injury
Secondary outcome [5] 0 0
Other Neurologic Outcomes: Montreal Cognitive Assessment Short-Term - Montreal Cognitive Assessment
Timepoint [5] 0 0
3-months post injury
Secondary outcome [6] 0 0
Primary Neurologic Outcome: Mid-Term - Modified Rankin Scale
Timepoint [6] 0 0
6-months post injury
Secondary outcome [7] 0 0
Other Neurologic Outcomes: NIH Stroke Scale Mid-Term - NIH Stroke Scale
Timepoint [7] 0 0
6-months post injury
Secondary outcome [8] 0 0
Other Neurologic Outcomes: Barthel Index Mid-Term - Barthel Index
Timepoint [8] 0 0
6-months post injury
Secondary outcome [9] 0 0
Other Neurologic Outcomes: Glasgow Outcome Scale Mid-Term - Glasgow Outcome Scale
Timepoint [9] 0 0
6-months post injury
Secondary outcome [10] 0 0
Other Neurologic Outcomes: Montreal Cognitive Assessment Mid-Term - Montreal Cognitive Assessment
Timepoint [10] 0 0
6-months post injury
Secondary outcome [11] 0 0
Primary Neurologic Outcome: Long-Term - Modified Rankin Scale
Timepoint [11] 0 0
12-months post injury
Secondary outcome [12] 0 0
Adverse Events - An untoward medical occurrence, unintended disease or injury, or unanticipated complication
Timepoint [12] 0 0
From date of randomization until hospital discharge, assessed up to 30 days
Secondary outcome [13] 0 0
Infection Rate - Healthcare associated infection
Timepoint [13] 0 0
From date of randomization until hospital discharge, assessed up to 30 days
Secondary outcome [14] 0 0
Incidence of Shivering - Shivering greater than or equal to 1 on the Bedside Shivering Assessment Scale
Timepoint [14] 0 0
Up to 14 days

Eligibility
Key inclusion criteria
1. Admitted with a primary neurological diagnosis of ischemic stroke, intracerebral
hemorrhage, or subarachnoid hemorrhage

2. Prior to onset of acute symptoms, was considered functionally independent (mRS 0-2)

3. Meets disease-specific criteria
Minimum age
21 Years
Maximum age
85 Years
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Fever (=38°C) prior to study enrollment

2. Pre-existing neurological, psychiatric, or other condition that would confound
neurological assessment or would make it difficult to accurately assess neurologic
and/or functional outcome

3. Has a pre-morbid condition with poor likelihood of survival to 6 months

4. Has a pre-morbid mRS =3

5. Diagnosed with brain death

6. Is undergoing therapeutic hypothermia therapy

7. Has sustained neurological injury felt to be catastrophic with little chance of
recovery

8. Has a skin condition in which the use of the ArcticGel Pads is contraindicated (i.e.,
skin that has signs of ulceration, burns, hives, or rash)

9. Has poor skin integrity or poor tissue perfusion

10. Participation in a concurrent investigational / interventional study (medical device
or drug)

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?


The people assessing the outcomes
Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 0 0
Royal North Shore Hospital - Sydney
Recruitment postcode(s) [1] 0 0
2065 - Sydney
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Colorado
Country [3] 0 0
United States of America
State/province [3] 0 0
Connecticut
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Illinois
Country [6] 0 0
United States of America
State/province [6] 0 0
Kentucky
Country [7] 0 0
United States of America
State/province [7] 0 0
Louisiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Maryland
Country [9] 0 0
United States of America
State/province [9] 0 0
Massachusetts
Country [10] 0 0
United States of America
State/province [10] 0 0
Michigan
Country [11] 0 0
United States of America
State/province [11] 0 0
Missouri
Country [12] 0 0
United States of America
State/province [12] 0 0
New Mexico
Country [13] 0 0
United States of America
State/province [13] 0 0
New York
Country [14] 0 0
United States of America
State/province [14] 0 0
North Carolina
Country [15] 0 0
United States of America
State/province [15] 0 0
Ohio
Country [16] 0 0
United States of America
State/province [16] 0 0
Oregon
Country [17] 0 0
United States of America
State/province [17] 0 0
Pennsylvania
Country [18] 0 0
United States of America
State/province [18] 0 0
Rhode Island
Country [19] 0 0
United States of America
State/province [19] 0 0
Tennessee
Country [20] 0 0
United States of America
State/province [20] 0 0
Texas
Country [21] 0 0
Austria
State/province [21] 0 0
Innsbruck
Country [22] 0 0
Germany
State/province [22] 0 0
Berlin
Country [23] 0 0
Germany
State/province [23] 0 0
Darmstadt
Country [24] 0 0
Germany
State/province [24] 0 0
Dresden
Country [25] 0 0
Germany
State/province [25] 0 0
Jena
Country [26] 0 0
Germany
State/province [26] 0 0
Munich
Country [27] 0 0
Korea, Republic of
State/province [27] 0 0
Seoul
Country [28] 0 0
Switzerland
State/province [28] 0 0
Zürich
Country [29] 0 0
United Kingdom
State/province [29] 0 0
England

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
C. R. Bard
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
Yale University
Address [1] 0 0
Country [1] 0 0
Other collaborator category [2] 0 0
Other
Name [2] 0 0
Boston University
Address [2] 0 0
Country [2] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
This study will assess the impact of fever prevention on fever burden and short- and
long-term neurologic outcomes in brain injured patients. Half of the subjects will undergo
fever prevention using a targeted temperature management system and half of the subjects will
be treated for fever should it develop.
Trial website
https://clinicaltrials.gov/show/NCT02996266
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
David M. Greer, MD, MA
Address 0 0
Boston University
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Peter Fayek
Address 0 0
Country 0 0
Phone 0 0
(847) 362-8796
Fax 0 0
Email 0 0
peter.fayek@bd.com
Contact person for scientific queries

Summary results
For IPD and results data, please see https://clinicaltrials.gov/show/NCT02996266